The Valley Desk

NCT04751383 · Interventional trial

Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

Overall registry status Terminated

Phase 1

Conditions High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov